Brokerages Set United Therapeutics Co. (NASDAQ:UTHR) Price Target at $370.86

United Therapeutics Co. (NASDAQ:UTHR) has been assigned a consensus rating of “Moderate Buy” from the fifteen analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $370.86.

UTHR has been the topic of a number of research analyst reports. Bank of America cut their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research note on Thursday, August 1st. LADENBURG THALM/SH SH upped their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. HC Wainwright lifted their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, Wells Fargo & Company lifted their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th.

Insider Activity at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 269 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $348.41, for a total value of $93,722.29. Following the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $45,293.30. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $344.18, for a total value of $1,239,048.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $44,743.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 269 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $45,293.30. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 113,396 shares of company stock valued at $42,175,418. Corporate insiders own 11.90% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

Institutional investors have recently modified their holdings of the company. ClariVest Asset Management LLC grew its position in United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares during the last quarter. V Square Quantitative Management LLC bought a new position in shares of United Therapeutics during the 2nd quarter valued at $30,000. Innealta Capital LLC purchased a new position in United Therapeutics in the 2nd quarter worth $33,000. USA Financial Formulas bought a new stake in United Therapeutics in the third quarter worth $33,000. Finally, Capital Performance Advisors LLP purchased a new stake in United Therapeutics during the third quarter valued at about $82,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Trading Up 0.1 %

Shares of NASDAQ:UTHR opened at $400.87 on Friday. The stock has a market cap of $17.90 billion, a PE ratio of 17.61, a price-to-earnings-growth ratio of 1.20 and a beta of 0.56. The stock’s fifty day simple moving average is $360.91 and its two-hundred day simple moving average is $325.71. United Therapeutics has a 1-year low of $208.62 and a 1-year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same period last year, the firm earned $5.38 earnings per share. The firm’s revenue was up 22.9% on a year-over-year basis. On average, sell-side analysts forecast that United Therapeutics will post 25.1 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.